The mechanism of the preventive effect on nocturnal hypoglycemia by sodium glucose cotransporter 2 inhibitors

The mechanism of the preventive effect on nocturnal hypoglycemia by sodium glucose cotransporter 2 inhibitors - The mechanism of the preventive effect on nocturnal hypoglycemia by SGLT 2 inhibitors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029550

Enrollment

Registered

2017-10-14

Start date

2017-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Basal-bolus insulin therapy Basal-bolus insulin therapy + canagliflozin Basal-bolus insulin therapy + dapagliflozin Basal-bolus insulin therapy + empagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The type 2 diabetes patients who had consented for hospitalization for diabetic control and education of diabetes.

Exclusion criteria

Exclusion criteria: Subjects were excluded if they had been previously treated with insulin; were positive for anti-glutamic acid decarboxylase antibody; or had history or evidence of any carcinoma, endocrine disease, recent myocardial infarction, heart failure, or cerebrovascular disease.

Design outcomes

Primary

Measure	Time frame
The frequency of the nocturnal hypoglycemia estimated by continuous glucose monitoring system. The levels of the gluconeogenesis inducible factors at 2 am.	—

Countries

Japan

Contacts

Public ContactFumitaka Okajima

Nippon Medical School Chiba-Hokusoh Hospital Division of Endocrinology, Department of Medicine

okaji@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026